Rise Men’s Health offers clinic-based testosterone care and an online service called eTRT. Its public telemedicine page identifies Texas as the current service area, making geography an early part of the decision. A convenient online appointment is useful only if the provider can actually care for you where you are.
We reviewed Rise’s service and pricing pages on September 21, 2026. The sources describe testing, insurance, and self-pay options, but they do not establish one complete quote for every patient. This is an assessment of published information, not firsthand treatment testing or verification of an individual insurance policy.
- Rise’s reviewed eTRT page identifies Texas as the current service area.
- The $150 entry fee and $99–$225 subscription descriptions need scope confirmation.
- Verify the diagnosis, actual prescription, and continuing monitoring.
Start with the Texas service boundary
Rise’s eTRT page says its online service is available statewide in Texas and invites people in other states to join a waiting list. General language about receiving care from anywhere should be read within that stated boundary. A plan to expand is not evidence that expansion has happened.
Ask Rise to confirm eligibility for your location before paying or transferring records. If you spend part of the year elsewhere, explain that during the first conversation and ask how follow-up would work. The Rise-versus-Thrivelab comparison looks at service areas alongside the clinical and payment questions.
Understand what the initial fee covers
The self-pay eTRT description lists a $150 one-time fee and says subscriptions start at $99 per month. It describes a provider video visit, laboratory orders through partner facilities, and consideration of recent results for people continuing care. It does not establish that the starting subscription price includes every possible assessment or prescription.
Request a written explanation of the first payment and which services it purchases. Ask whether a laboratory order includes the laboratory’s charge, how qualifying outside results are handled, and what you owe if further evaluation does not support treatment. A fee for an assessment should not be interpreted as the purchase of a guaranteed prescription.
Read the subscription qualification carefully
Rise’s TRT Basics page gives a $99–$225 monthly subscription range. It describes initial care, laboratory work, follow-ups, and prescription needs, with a qualification based on one year of injection services. That wording needs clarification before treating the lowest amount as a freely cancellable monthly offer.
Ask which tier applies, whether a minimum service commitment is involved, when payments occur, and what happens if the clinician changes the plan. We have not verified that a full year must be paid upfront. Use the cost worksheet only after Rise supplies the actual terms for the proposed care.
Treat insurance language as a starting point
Rise promotes insurance use for its service and gives illustrative copay figures. Those figures do not settle the reader’s deductible, coinsurance, network status, laboratory bill, or prescription coverage. The provider’s general explanation should not be used as a substitute for checking the exact plan and clinical services.
Ask which organization bills each part of care and whether authorization or other documentation is required. Request an estimate of patient responsibility and ask how a denied claim is handled. A broad claim about insurance covering TRT does not guarantee that every proposed medication or service will be paid for.
Look for a confirmed diagnosis before treatment
Rise’s testing description discusses testosterone samples collected on separate mornings before treatment decisions. The Endocrine Society’s guidance calls for compatible symptoms or signs together with consistently low testosterone and confirmation using repeat morning testing. The clinician also needs to consider what caused the low result.
Bring previous laboratory reports with collection times and a current medicine list. Follow the treating clinician’s preparation instructions rather than a generic website statement. Our testing guide explains why fatigue, a questionnaire score, or one number cannot by itself establish the need for testosterone replacement.
Ask about the exact product and home support
Rise describes both office treatment and self-injection support within its broader service information. That does not establish a specific brand, concentration, manufacturer, or dispensing pharmacy for your prescription. Ask the clinician to identify the proposed product and whether it is an approved finished medicine or a compounded preparation.
Compounded drugs are not FDA-approved. If one is proposed, ask why it meets your clinical need and what other suitable options exist. Obtain instructions for the actual medicine and a clear pharmacy contact. Our delivery-method comparison can help you discuss practical needs without choosing a route or schedule yourself.
Compare ongoing care before choosing the service
Ask how the team follows symptoms, blood pressure, blood count, hormone results, and relevant prostate concerns. Find out who reviews unexpected results and whether an additional appointment changes the price. A home-injection plan still needs a clinical process for deciding whether the medicine remains appropriate.
Rise may be relevant to eligible Texas readers who want remote follow-up linked to a clinic team, provided the full terms are confirmed. Read the Rise-versus-Limitless Male comparison for a different attendance model. This review does not establish superior outcomes, universal insurance coverage, or suitability for a particular patient.
Sources & reading notes
Provider pages describe advertised services, not independently verified outcomes. Prices and eligibility may change. Research checked September 21, 2026. Article updated September 21, 2026.
- Rise: eTRT Texas availability, self-pay entry fee, and insurance descriptions
- Rise Men’s Health: clinic and prescribing-service overview
- Rise: TRT testing, subscription scope, and annual-service qualification
- Endocrine Society: testosterone therapy clinical practice guideline
- FDA: understanding the risks of compounded drugs
- FDA: 2025 testosterone labeling changes and blood pressure warnings